Fetal bovine serum market seen reaching $2.31 billion by 2035

Market Research Future projects the global fetal bovine serum market will grow from $1.30 billion in 2025 to $2.31 billion by 2035, driven by cell and gene therapy demand, biopharmaceutical R&D spending and tighter cattle supply. The forecast also points to rising compliance costs and premium pricing for traceable, specialty serum grades.

Why it matters: - Fetal bovine serum remains a core input for mammalian cell culture, so demand tracks directly with drug development, cell therapy manufacturing and vaccine work. - Tighter supply and stricter traceability rules are supporting pricing power for established suppliers. - The market’s growth reflects a broader shift toward more complex biologics and regenerative medicine programs.

What happened: - Market Research Future projected the global fetal bovine serum market will rise from $1.30 billion in 2025 to $2.31 billion by 2035. - The forecast implies a 5.8% compound annual growth rate from 2026 to 2035. - The first forecast year, 2026, is valued at $1.39 billion. - The report said the market’s expansion is being driven by cell and gene therapy pipeline growth and biopharmaceutical R&D investment. - The report was published Aug. 27, 2026. - Request a free sample

The details: - The report said the global cell and gene therapy pipeline now exceeds 3,200 active clinical assets. - The U.S. cattle herd fell to 86.7 million head in January 2025, the lowest level since 1951, tightening raw-material supply. - Global biopharmaceutical R&D spending exceeded $265 billion in 2024. - ISIA accreditation and EU regulatory criteria now require full geographic traceability from abattoir to end user. - The European Medicines Agency has strengthened TSE/BSE risk-mitigation documentation for serum used in biologics manufacturing. - Charcoal/dextran-stripped serum held the largest product share in 2025 at 34.1%. - Stem-cell-qualified FBS was the fastest-growing product category, with a 6.7% CAGR from 2026 to 2035. - Heat-inactivated serum is projected to grow at a 5.2% CAGR. - Biopharmaceutical production was the largest application in 2025 at 29.5% share. - Cell-culture maintenance and expansion was the fastest-growing application, with a 7.2% CAGR. - Biotechnology and pharmaceutical companies were the largest end-user group in 2025, with a 57.4% share. - Academic and research institutes were the fastest-growing end-user category, with a 7.3% CAGR. - North America led the market in 2025 with a 38.2% share. - Europe was the second-largest region in 2025 with a 28.5% share. - Asia-Pacific was the fastest-growing region, with a 6.7% CAGR from 2026 to 2035. - South America accounted for $0.08 billion in 2025. - The Middle East and Africa held a 4.7% share in 2025. - Read the detailed report

Between the lines: - The report points to a market that is becoming harder to enter, because compliance demands favor suppliers with traceability systems and specialized processing infrastructure. - Supply constraints matter because fetal bovine serum has no synthetic substitute at scale, which limits how quickly the market can respond to demand spikes. - Specialty grades are gaining more value as precision assays and regenerative medicine programs expand. - The report also suggests regional growth is shifting toward Asia-Pacific, where CRO and CMO capacity is expanding quickly.

What's next: - The market is expected to keep growing through 2035, but supply scarcity may continue to limit volume expansion. - Premium grades such as charcoal/dextran-stripped and stem-cell-qualified serum are likely to capture more demand. - Digital traceability tools and blockchain-based lot tracking may become more important as buyers seek verified origin and performance data. - Ongoing expansion in cell and gene therapy, vaccine development and biopharma R&D should keep serum demand elevated.

The bottom line: - Fetal bovine serum is still a must-have consumable for cell-based life sciences, and the combination of rising therapeutic demand, supply tightness and stricter regulation is set to keep the market on a steady upward path.